The present invention provides a low-molecular inhibitor of GIP functions
and, further, an agent for preventing/ameliorating obesity based on
inhibition of GIP functions, which comprises, as an active ingredient, a
compound represented by the following general formula (I): 1
(wherein R.sup.1 represents hydrogen, halogen, a nitro group or a cyano
group, R.sup.2 and R.sup.3 each represent hydrogen or halogen, hydrogen
or a methoxy group, or both R.sup.2 and R.sup.3 may form an optionally
substituted benzene or pyrrole ring, and A represents nitrogen or
C--R.sup.4 whereupon R.sup.4 represents hydrogen, an optionally
substituted C1 to C6 alkyl group, --OR.sup.7, --NR.sup.8R.sup.9,
--NHCO--R.sup.1 or --SO.sub.2--R or may, together with R.sup.3, form an
optionally substituted benzene or pyrrole ring, R.sup.7, R.sup.8 and
R.sup.9 each represent hydrogen or an optionally substituted C1 to C6
alkyl group, R.sup.10 represents a C1 to C6 alkyl group or the like, and
R.sup.1 represents an optionally substituted morpholyl group or the like)
or a pharmaceutically acceptable salt thereof.
